Vertex Pharmaceuticals Boosted by Goldman Sachs Conviction List

Vertex Pharmaceuticals' shares are trading at $546, but price targets vary widely among analysts. Goldman Sachs is firmly in the bull camp, with a 'buy' rating and a $653 price target on the stock.

The bank recently added Vertex to its highest-conviction list, which suggests strong confidence in the company's prospects. Vertex develops innovative medicines for rare conditions, including cystic fibrosis (CF), a disease that causes thick mucus to form in the lungs.

The company has nearly complete pricing power in the CF market due to limited competition. Its core business generates consistent revenue and earnings, with growth expected until its most important drugs lose patent exclusivity in the late 2030s.